Alpha-blocker treatment response in men with lower urinary tract symptoms based on sympathetic activity: Prospective, multicenter, open-labeled, observational study

Sung Gon Park, Byung Ha Chung, Sung Won Lee, Jong Kwan Park, Kwangsung Park, Jun Cheon, Kyung Seop Lee, Hyung Jee Kim, Do Hwan Seong, Seung June Oh, Sae Woong Kim, Ji Youl Lee, Seol Ho Choo, Jong Bo Choi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose: In this study, we compared the treatment outcomes for an a-blocker between 2 groups of men, one with high sympathetic activity (HSA) and another with low sympathetic activity (LSA) or normal sympathetic activity. Methods: A total of 159 men (≥50 years of age) with lower urinary tract symptoms resulting from benign prostatic hyperplasia were analyzed. We assigned patients to groups according to their sympathetic activity, which was evaluated by heart rate variability measurements. HSA was defined as a low frequency/high frequency ratio greater than 1.6. All patients received 10 mg of alfuzosin once a day for 12 weeks. The primary end point was a change in the total International Prostate Symptom Score (IPSS) at 12 weeks from baseline. Results: Sixty-seven men were assigned to the HSA group and 92 men were assigned to the LSA group. The baseline characteristics were not significantly different between the 2 groups, and the response to alfuzosin was good in both groups. The mean total IPSS change was not different between the groups. Both groups were not significantly different with respect to the changes in maximal flow rate, IPSS voiding or storage symptom subscores, quality of life, and rates of adverse drug events. The HSA group showed a similar willingness to continue treatment compared to the LSA group, although their treatment satisfaction rating was lower. Conclusions: The therapeutic effects of alfuzosin did not differ in regards to the differences in sympathetic activity, but treatment satisfaction ratings were lower in the HSA group.

Original languageEnglish
Pages (from-to)107-112
Number of pages6
JournalInternational Neurourology Journal
Volume19
Issue number2
DOIs
Publication statusPublished - 2015 Jan 1

Fingerprint

Lower Urinary Tract Symptoms
Observational Studies
Prostate
Prostatic Hyperplasia
Therapeutic Uses
Therapeutics
Drug-Related Side Effects and Adverse Reactions
Heart Rate
Quality of Life
alfuzosin

Keywords

  • Heart rate
  • Lower urinary tract symptoms
  • Prostatic hyperplasia
  • Sympathetic nervous system

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Urology

Cite this

Alpha-blocker treatment response in men with lower urinary tract symptoms based on sympathetic activity : Prospective, multicenter, open-labeled, observational study. / Park, Sung Gon; Chung, Byung Ha; Lee, Sung Won; Park, Jong Kwan; Park, Kwangsung; Cheon, Jun; Lee, Kyung Seop; Kim, Hyung Jee; Seong, Do Hwan; Oh, Seung June; Kim, Sae Woong; Lee, Ji Youl; Choo, Seol Ho; Choi, Jong Bo.

In: International Neurourology Journal, Vol. 19, No. 2, 01.01.2015, p. 107-112.

Research output: Contribution to journalArticle

Park, Sung Gon ; Chung, Byung Ha ; Lee, Sung Won ; Park, Jong Kwan ; Park, Kwangsung ; Cheon, Jun ; Lee, Kyung Seop ; Kim, Hyung Jee ; Seong, Do Hwan ; Oh, Seung June ; Kim, Sae Woong ; Lee, Ji Youl ; Choo, Seol Ho ; Choi, Jong Bo. / Alpha-blocker treatment response in men with lower urinary tract symptoms based on sympathetic activity : Prospective, multicenter, open-labeled, observational study. In: International Neurourology Journal. 2015 ; Vol. 19, No. 2. pp. 107-112.
@article{fd13e979799c49ed9d1cb7488b3e11f9,
title = "Alpha-blocker treatment response in men with lower urinary tract symptoms based on sympathetic activity: Prospective, multicenter, open-labeled, observational study",
abstract = "Purpose: In this study, we compared the treatment outcomes for an a-blocker between 2 groups of men, one with high sympathetic activity (HSA) and another with low sympathetic activity (LSA) or normal sympathetic activity. Methods: A total of 159 men (≥50 years of age) with lower urinary tract symptoms resulting from benign prostatic hyperplasia were analyzed. We assigned patients to groups according to their sympathetic activity, which was evaluated by heart rate variability measurements. HSA was defined as a low frequency/high frequency ratio greater than 1.6. All patients received 10 mg of alfuzosin once a day for 12 weeks. The primary end point was a change in the total International Prostate Symptom Score (IPSS) at 12 weeks from baseline. Results: Sixty-seven men were assigned to the HSA group and 92 men were assigned to the LSA group. The baseline characteristics were not significantly different between the 2 groups, and the response to alfuzosin was good in both groups. The mean total IPSS change was not different between the groups. Both groups were not significantly different with respect to the changes in maximal flow rate, IPSS voiding or storage symptom subscores, quality of life, and rates of adverse drug events. The HSA group showed a similar willingness to continue treatment compared to the LSA group, although their treatment satisfaction rating was lower. Conclusions: The therapeutic effects of alfuzosin did not differ in regards to the differences in sympathetic activity, but treatment satisfaction ratings were lower in the HSA group.",
keywords = "Heart rate, Lower urinary tract symptoms, Prostatic hyperplasia, Sympathetic nervous system",
author = "Park, {Sung Gon} and Chung, {Byung Ha} and Lee, {Sung Won} and Park, {Jong Kwan} and Kwangsung Park and Jun Cheon and Lee, {Kyung Seop} and Kim, {Hyung Jee} and Seong, {Do Hwan} and Oh, {Seung June} and Kim, {Sae Woong} and Lee, {Ji Youl} and Choo, {Seol Ho} and Choi, {Jong Bo}",
year = "2015",
month = "1",
day = "1",
doi = "10.5213/inj.2015.19.2.107",
language = "English",
volume = "19",
pages = "107--112",
journal = "International Neurourology Journal",
issn = "2093-4777",
publisher = "Korean Association of Medical Journal Edirors",
number = "2",

}

TY - JOUR

T1 - Alpha-blocker treatment response in men with lower urinary tract symptoms based on sympathetic activity

T2 - Prospective, multicenter, open-labeled, observational study

AU - Park, Sung Gon

AU - Chung, Byung Ha

AU - Lee, Sung Won

AU - Park, Jong Kwan

AU - Park, Kwangsung

AU - Cheon, Jun

AU - Lee, Kyung Seop

AU - Kim, Hyung Jee

AU - Seong, Do Hwan

AU - Oh, Seung June

AU - Kim, Sae Woong

AU - Lee, Ji Youl

AU - Choo, Seol Ho

AU - Choi, Jong Bo

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Purpose: In this study, we compared the treatment outcomes for an a-blocker between 2 groups of men, one with high sympathetic activity (HSA) and another with low sympathetic activity (LSA) or normal sympathetic activity. Methods: A total of 159 men (≥50 years of age) with lower urinary tract symptoms resulting from benign prostatic hyperplasia were analyzed. We assigned patients to groups according to their sympathetic activity, which was evaluated by heart rate variability measurements. HSA was defined as a low frequency/high frequency ratio greater than 1.6. All patients received 10 mg of alfuzosin once a day for 12 weeks. The primary end point was a change in the total International Prostate Symptom Score (IPSS) at 12 weeks from baseline. Results: Sixty-seven men were assigned to the HSA group and 92 men were assigned to the LSA group. The baseline characteristics were not significantly different between the 2 groups, and the response to alfuzosin was good in both groups. The mean total IPSS change was not different between the groups. Both groups were not significantly different with respect to the changes in maximal flow rate, IPSS voiding or storage symptom subscores, quality of life, and rates of adverse drug events. The HSA group showed a similar willingness to continue treatment compared to the LSA group, although their treatment satisfaction rating was lower. Conclusions: The therapeutic effects of alfuzosin did not differ in regards to the differences in sympathetic activity, but treatment satisfaction ratings were lower in the HSA group.

AB - Purpose: In this study, we compared the treatment outcomes for an a-blocker between 2 groups of men, one with high sympathetic activity (HSA) and another with low sympathetic activity (LSA) or normal sympathetic activity. Methods: A total of 159 men (≥50 years of age) with lower urinary tract symptoms resulting from benign prostatic hyperplasia were analyzed. We assigned patients to groups according to their sympathetic activity, which was evaluated by heart rate variability measurements. HSA was defined as a low frequency/high frequency ratio greater than 1.6. All patients received 10 mg of alfuzosin once a day for 12 weeks. The primary end point was a change in the total International Prostate Symptom Score (IPSS) at 12 weeks from baseline. Results: Sixty-seven men were assigned to the HSA group and 92 men were assigned to the LSA group. The baseline characteristics were not significantly different between the 2 groups, and the response to alfuzosin was good in both groups. The mean total IPSS change was not different between the groups. Both groups were not significantly different with respect to the changes in maximal flow rate, IPSS voiding or storage symptom subscores, quality of life, and rates of adverse drug events. The HSA group showed a similar willingness to continue treatment compared to the LSA group, although their treatment satisfaction rating was lower. Conclusions: The therapeutic effects of alfuzosin did not differ in regards to the differences in sympathetic activity, but treatment satisfaction ratings were lower in the HSA group.

KW - Heart rate

KW - Lower urinary tract symptoms

KW - Prostatic hyperplasia

KW - Sympathetic nervous system

UR - http://www.scopus.com/inward/record.url?scp=84934768320&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84934768320&partnerID=8YFLogxK

U2 - 10.5213/inj.2015.19.2.107

DO - 10.5213/inj.2015.19.2.107

M3 - Article

AN - SCOPUS:84934768320

VL - 19

SP - 107

EP - 112

JO - International Neurourology Journal

JF - International Neurourology Journal

SN - 2093-4777

IS - 2

ER -